Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.576
EU - Europa 5.230
AS - Asia 2.508
SA - Sud America 177
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 10
Totale 16.554
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.443
IT - Italia 1.371
SG - Singapore 1.095
DE - Germania 868
RU - Federazione Russa 754
CN - Cina 702
IE - Irlanda 639
SE - Svezia 542
HK - Hong Kong 362
UA - Ucraina 287
GB - Regno Unito 213
BR - Brasile 145
CA - Canada 127
FR - Francia 121
FI - Finlandia 106
ID - Indonesia 87
IN - India 81
PL - Polonia 74
BE - Belgio 63
NL - Olanda 50
TR - Turchia 47
VN - Vietnam 47
DK - Danimarca 36
AT - Austria 24
ES - Italia 22
IR - Iran 15
EU - Europa 14
JP - Giappone 13
MA - Marocco 12
KR - Corea 11
PE - Perù 11
AR - Argentina 10
AU - Australia 9
CH - Svizzera 8
LT - Lituania 8
ZA - Sudafrica 7
CZ - Repubblica Ceca 6
RO - Romania 6
EG - Egitto 5
MX - Messico 5
NO - Norvegia 5
AZ - Azerbaigian 4
BD - Bangladesh 4
BG - Bulgaria 4
CL - Cile 4
MK - Macedonia 4
PK - Pakistan 4
CO - Colombia 3
GR - Grecia 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
EC - Ecuador 2
IQ - Iraq 2
JO - Giordania 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MU - Mauritius 2
NP - Nepal 2
PT - Portogallo 2
PY - Paraguay 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TN - Tunisia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
KH - Cambogia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
YE - Yemen 1
Totale 16.554
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Woodbridge 726
Fairfield 689
Singapore 645
Dublin 629
Chandler 602
Frankfurt am Main 601
Milan 560
Wilmington 444
Ashburn 412
Houston 410
Hong Kong 359
Jacksonville 267
Seattle 253
Cambridge 247
Dearborn 247
New York 238
Santa Clara 198
Princeton 172
Nanjing 124
Shanghai 122
Jakarta 85
Altamura 83
Lawrence 79
Beijing 73
Lodz 70
Brussels 59
Helsinki 54
San Diego 47
Lachine 44
Moscow 44
Boardman 41
Los Angeles 41
Guangzhou 39
Fremont 38
Council Bluffs 37
Lissone 36
Nuremberg 36
Shenyang 34
Munich 32
Nanchang 32
Andover 31
Toronto 31
Rome 30
Ottawa 29
Romola 29
Göttingen 27
Chicago 25
Jinan 22
Carate Brianza 21
Falls Church 21
Jiaxing 21
London 21
Hebei 20
Kunming 20
Monza 20
Mountain View 19
Norwalk 19
Tianjin 19
Düsseldorf 18
Kocaeli 17
Pune 17
Dong Ket 16
Edmonton 16
Hangzhou 16
Desio 15
Lauterbourg 15
Turin 15
São Paulo 14
Redmond 13
Changsha 12
Sesto San Giovanni 12
Como 11
Kiev 11
Taizhou 11
Bari 10
Casablanca 10
Cesano Maderno 10
Genoa 10
Seregno 10
Zhengzhou 10
Bonndorf 9
Cinisello Balsamo 9
Fürstenwalde 9
Lima 9
Paris 9
Hefei 8
Vienna 8
Washington 8
Amsterdam 7
Changchun 7
Daejeon 7
Detroit 7
Huizen 7
Mumbai 7
Phoenix 7
Riva del Garda 7
Boston 6
Buenos Aires 6
Duncan 6
Totale 11.745
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 371
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 336
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 306
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 293
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 286
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 275
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 275
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 271
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 257
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 240
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 239
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 231
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 228
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 226
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 226
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 224
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 216
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 211
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 209
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 209
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 209
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 208
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 206
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 204
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 201
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 200
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 199
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 198
Inhibition of RET tyrosine kinase by SU5416 197
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 191
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 190
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 189
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 189
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 187
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 187
Expression, purification, and inhibition of human RET tyrosine kinase 186
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 183
We shall overcome (drug resistance) some day 182
Dual kinase targeting in leukemia 181
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 180
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 177
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 175
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 175
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 174
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 173
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 170
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 169
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 165
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 160
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 157
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 157
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 157
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 155
Novel targeted therapeutics for MEN2 154
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 146
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 145
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 145
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 143
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 141
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 140
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 139
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 135
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 129
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 128
Anaplastic Lymphoma kinase assay, reagents and composition thereof 127
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 127
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 125
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 124
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 123
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 123
New developments in the treatment of ALK-driven malignancies 123
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 122
RET kinase inhibitors: a review of recent patents (2012–2015) 119
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 118
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 115
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 114
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 114
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 113
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 110
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 110
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells 108
Expanding the portfolio of anti-ALK weapons 105
Characterization of mouse myotilin and its promoter 105
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 105
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 103
Targeting drug resistance mutations: Discovery of EUD-GK-91 chemical series 102
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 100
Role of TMPRSS2/ERG in cellular transformation 99
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead 99
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 98
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 98
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 95
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 90
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 90
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells 88
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 87
Development of RET kinase inhibitors for targeted cancer therapy 85
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 84
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 76
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 74
Totale 16.503
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020391 0 0 0 0 0 0 0 0 0 171 159 61
2020/20212.141 93 107 204 252 168 208 179 214 187 204 151 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20253.798 275 476 319 278 440 200 369 193 548 700 0 0
Totale 17.250